Inactive Instrument

Analyst Reco. RayzeBio, Inc.

Equities

JPMorgan Downgrades RayzeBio to Neutral From Overweight, Adjusts Price Target to $62.50 From $30	12-28	MT
Truist Securities Downgrades RayzeBio to Hold From Buy, Raises Price Target to $62.50 From $29	12-27	MT
North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	12-27	DJ
William Blair Downgrades RayzeBio to Market Perform From Outperform	12-26	MT
Evercore ISI Initiates RayzeBio at Outperform Rating	11/10/23	MT
Truist Securities Initiates RayzeBio With Buy Rating, Price Target is $29	10/10/23	MT
JPMorgan Starts RayzeBio at Overweight With $30 Price Target	10/10/23	MT
Jefferies Starts RayzeBio at Buy With $35 Price Target	10/10/23	MT
William Blair Starts RayzeBio at Outperform	06/10/23	MT

No results for this search